Oncology News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files its first CAR-T therapy cilta-cel in Europe

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

News

Keytruda should lose stomach cancer indication, says ODAC

The FDA's Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co's Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) cancer, despite a

News

Tecentriq can stay as therapy for triple-negative breast can...

Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs.

News

FDA looks at pulling speedy approvals for three cancer drugs

FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market.

News

J&J decides against Erleada+Zytiga combination prostate canc...

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it didn’t improve survival compared with

News

Astellas, Seagen seek speedy reviews of Padcev in bladder ca...

The next milestone in Seagen and Astellas' bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster will come in August, when the FDA concludes an accelerated review of tw

Janssen files its first CAR-T therapy cilta-cel in Europe

Keytruda should lose stomach cancer indication, says ODAC

Tecentriq can stay as therapy for triple-negative breast can...

FDA looks at pulling speedy approvals for three cancer drugs

J&J decides against Erleada+Zytiga combination prostate canc...

Astellas, Seagen seek speedy reviews of Padcev in bladder ca...

NICE recommends wider use of Biogen MS drug via NHS

How to meet your physicians where they are online

News

Editor's Picks